Fennec Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FENC research report →
Companywww.fennecpharma.com
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
- CEO
- Jeffrey S. Hackman
- IPO
- 2017
- Employees
- 32
- HQ
- Research Triangle Park, NC, US
Price Chart
Valuation
- Market Cap
- $278.66M
- P/E
- -39.97
- P/S
- 5.46
- P/B
- 8.89
- EV/EBITDA
- -34.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.23%
- Op Margin
- -11.02%
- Net Margin
- -16.42%
- ROE
- -55.13%
- ROIC
- -9.03%
Growth & Income
- Revenue
- $44.64M · -6.09%
- Net Income
- $-9,741,000 · -2134.17%
- EPS
- $-0.36 · -2150.00%
- Op Income
- $-6,346,000
- FCF YoY
- -146.23%
Performance & Tape
- 52W High
- $10.27
- 52W Low
- $5.65
- 50D MA
- $6.98
- 200D MA
- $7.94
- Beta
- 0.91
- Avg Volume
- 226.61K
Get TickerSpark's AI analysis on FENC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | RALLIS CHRIS A | other | 14,344 |
| May 11, 26 | RALLIS CHRIS A | other | 14,344 |
| May 11, 26 | RALLIS CHRIS A | sell | 8,346 |
| May 1, 26 | Raykov Rosty | other | 15,598 |
| May 1, 26 | Raykov Rosty | other | 15,598 |
| May 1, 26 | Raykov Rosty | sell | 10,781 |
| Apr 30, 26 | Raykov Rosty | other | 2,778 |
| Apr 30, 26 | Evans Terry L | other | 168 |
| Apr 30, 26 | Cioffi Christiana Marie | other | 155 |
| Apr 30, 26 | Hackman Jeffrey S. | other | 1,159 |
Our FENC Coverage
We haven't published any research on FENC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FENC Report →